Consistent with a vital role in assisting tumors of PD-L1+ mast cells in vivo, mice treated with T cells plus PD-L1 blocking antibody-treated TCM showed reduced tumor volumes and disease progression at each measuring time point from day 19 (Fig. 6a and b). This evidence concerns the gene CD274 and neoplasm.